Synthetic Biologics is a clinical-stage biotechnology company that develops pathogen-specific therapies for serious infections and diseases with a focus on protecting the microbiome. SYN is developing an oral biologic to protect the gut microbiome (gastrointestinal microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection; an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C); and a monoclonal antibody combination for the treatment of Pertussis. For more information, visit the company’s website at www.syntheticbiologics.com